A practical reference on Fragment designation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-30 and is reviewed periodically as new material appears.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
2 H2O2 → 2 H2O + O2 The rate of decomposition increases with rise in temperature, concentration, and pH. H2O2 is unstable under alkaline conditions. Decomposition is catalysed by various redox-active ions or compounds, including most transition metals and their compounds (e.g. manganese dioxide (MnO2), silver, and platinum).
Joullié (born 1927), Brazilian, American organic chemist Isabella Karle (1921–2017), American crystallographer Joyce Jacobson Kaufman (1929–2016), American chemist, Pharmacologist Judith Klinman (born 1941), American biochemist Teresa Kowalska (1946-2023), Polish chemist, co-founder of Acta Chromatographia Marisa Kozlowski, American organic chemist Stephanie Kwolek (1923–2014), American chemist, inventor of Kevlar Sine Larsen (1943–2025), Danish structural chemist and crystallographer Kathleen Lonsdale (1903–1971), British crystallographer Yvonne Connolly Martin (born 1936), American physical biochemist working on cheminformatics and computer-aided drug design in the US Marie Marynard Daly (1921–2001), First African American woman to earn her PhD in the United States Cynthia A.
Ollie captures her and withholds her Joy, forcing her to remember that she had helped the Germans during the Very Bad Thing. Both aware of the city's true history, Ollie informs her that the city's food has run out and implores her to help him reveal these truths to save the people. Victoria agrees, but when Ollie releases her, she attacks him and escapes. After finding the town's executive committee too addled on Joy to pay any mind to the tanks or the famine, Ollie decides to confront Uncle Jack (Julian Casey), Wellington Wells' friendly celebrity propagandist. Ollie infiltrates his broadcasting studio above City Hall, but he finds the studio is abandoned and Jack is missing. He plays a tape of his final but unreleased broadcast, in which Jack suffers an emotional breakdown brought about by resurfacing memories of his daughter Margaret and despairs over the town's hopeless situation. Ollie finally realizes that Margaret was actually Jack's daughter; Jack had tried to hide her from the Germans, but Ollie (who was their neighbor and hated Jack for being a collaborator) informed on them, and she was shot trying to flee. Now willing to atone, Ollie broadcasts the unreleased tape to the city, awakening the population. He then bids farewell to Margaret and builds a hot air balloon that he rides out of Wellington Wells.
Sources: en.wikipedia.org
== External links == whatisbifidusregularis.org/ – A deconstruction of the terms Bifidus Actiregularis, Bifidus Regularis, Bifidus Digestivum, L. Casei Immunitas and their variants, as well as the marketing strategy, and information about the potential health benefits of live yoghurts. Food-Info.net – How to select a probiotic Type strain of Bifidobacterium animalis at BacDive – the Bacterial Diversity Metadatabase
On 16 March 1935, Deputy Premier Alick McCallum resigned from the Ministry and from Parliament. On 26 March, Frank Wise filled the vacancy in the Executive Council whilst a reshuffle took place amongst some of the lower-order ministers.
=== Soundtrack === The soundtrack for The Orange Box consists of music that Valve employees composed for Half-Life 2: Episode One, Half-Life 2: Episode Two, Portal, and Team Fortress 2. It also includes the original version and an exclusive remix of "Still Alive", both by Jonathan Coulton. It was released on December 21, 2007, and is sold by the official Valve Store, Amazon.com, and digital music services such as iTunes, Napster, and eMusic. A more-complete version of this soundtrack that also includes music files from Half-Life and Half-Life 2 was released on Steam as part of the Audiosurf package. "Still Alive" was subsequently released as a free downloadable song for the rhythm game Rock Band on March 31, 2008.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.